Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
https://bit.ly/3phrbJU
Apologies if posted already - tweet from IG Analyst - https://bit.ly/3lT9b6M
yeah @Mikey279 they tell us bugger all apart from the stuff below. You make a fair amount of, potentially, libellous statements - so in the bin with you - specifically for being a moaning bore
06/09/2021 New appointments to Scientific Advisory Board
02/09/2021 Appointment of Chief Scientific Officer
11/08/2021 First Patient Dosed in AVA6000 Phase 1 Trial
04/08/2021 Update on AffiDX Lateral Flow Test
14/07/2021 Diagnostics achieves ISO 13485 Certification
29/06/2021 AffiDX Lateral Flow Test Detects Delta Variant
21/06/2021 AffiDX Lateral Flow Test Distribution Agreement
11/06/2021 Registration of AffiDX Lateral Flow Test in EU
07/06/2021 MHRA Confirms Registration of Lateral Flow Test
01/06/2021 Update on Lateral Flow Test Regulatory Submissions
10/05/2021 AffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
20/04/2021 Clinical validation of AffiDX Lateral Flow Test
06/04/2021 Distribution Agreement with ABCAM plc
09/03/2021 Diagnostic Licensing Deal with Biokit
08/03/2021 Rapid Antigen Test Detects SARS-CoV-2 Variants
18/02/2021 Phase I CTA for AVA6000 Approved by MHRA
16/02/2021 Results of Initial Evaluation of SARS-CoV-2 LFT
08/02/2021 Commercial Partnership with Mologic
01/02/2021 AffyXell $7.3 Million Series A Financing
28/01/2021 Collaboration Agreement with Bruker
07/01/2021 License Agreement with POINT Biopharma Inc.
23/12/2020 Submission of CTA for AVA6000 Pro-doxorubixin
21/12/2020 License Agreement with Astrea Bioseparations
23/11/2020 SARS-CoV-2 Rapid Antigen Test Update
30/09/2020 Launch of SARS-CoV-2 BAMS Research Test
24/09/2020 Update on Integumen Collaboration
07/09/2020 Avacta to Launch SARS-CoV-2 ELISA Laboratory Test
02/09/2020 Expansion of COVID-19 Test Manufacturing Capacity
18/08/2020 Expanded Partnership with LG Chem Life Sciences
Handy reminder of the progress made in the last 12 months, or so, for all long-term holders (minus normal company noise). For all the trolls - comment away - all I see will be little green boxes - which makes me happy.
06/09/2021 New appointments to Scientific Advisory Board
02/09/2021 Appointment of Chief Scientific Officer
11/08/2021 First Patient Dosed in AVA6000 Phase 1 Trial
04/08/2021 Update on AffiDX Lateral Flow Test
14/07/2021 Diagnostics achieves ISO 13485 Certification
29/06/2021 AffiDX Lateral Flow Test Detects Delta Variant
21/06/2021 AffiDX Lateral Flow Test Distribution Agreement
11/06/2021 Registration of AffiDX Lateral Flow Test in EU
07/06/2021 MHRA Confirms Registration of Lateral Flow Test
01/06/2021 Update on Lateral Flow Test Regulatory Submissions
10/05/2021 AffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
20/04/2021 Clinical validation of AffiDX Lateral Flow Test
06/04/2021 Distribution Agreement with ABCAM plc
09/03/2021 Diagnostic Licensing Deal with Biokit
08/03/2021 Rapid Antigen Test Detects SARS-CoV-2 Variants
18/02/2021 Phase I CTA for AVA6000 Approved by MHRA
16/02/2021 Results of Initial Evaluation of SARS-CoV-2 LFT
08/02/2021 Commercial Partnership with Mologic
01/02/2021 AffyXell $7.3 Million Series A Financing
28/01/2021 Collaboration Agreement with Bruker
07/01/2021 License Agreement with POINT Biopharma Inc.
23/12/2020 Submission of CTA for AVA6000 Pro-doxorubixin
21/12/2020 License Agreement with Astrea Bioseparations
23/11/2020 SARS-CoV-2 Rapid Antigen Test Update
30/09/2020 Launch of SARS-CoV-2 BAMS Research Test
24/09/2020 Update on Integumen Collaboration
07/09/2020 Avacta to Launch SARS-CoV-2 ELISA Laboratory Test
02/09/2020 Expansion of COVID-19 Test Manufacturing Capacity
18/08/2020 Expanded Partnership with LG Chem Life Sciences
TEMPLAR. the video was titled "Avacta CEO, Alastair Smith and Chief Development Officer Neil Bell, discuss their pre|CISION™ technology and the phase I trial evaluating AVA6000, a pro-drug of Doxorubicin. The go on to discuss the structure of the trial and dose escalation and dose expansion phases and their expectations from the trials."
If it was entitled "how to stop TEMPLAR wetting the bed" then your point is valid - just another pointless post from a pointless poster - get in the bin
"If you have a problem, if no one else can help, and if you can find them, maybe you can hire... Myles McNulty" - cue music - https://bit.ly/3jNRx1H
Anyone got an idea when their short position is due to close? Obviously I would love it if they got squeezed!
Feels like that's why the SP has been dragged down and kept down. One RNS with commercial partner sales, or home use cert, should blow them out of the water.
Hey Wiggly - similar - though my max top up was 260- not that that is much better. Think MylesM put it well on twitter earlier - SP is being judged on sales. Seems fair - so currently will hold my nose for a while longer and buy more :-)